Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …

Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …

Background Given the importance of flexible use of different COVID-19 vaccines within the
same schedule to facilitate rapid deployment, we studied mixed priming schedules …

Background COVID-19 vaccine supply shortages are causing concerns about compromised
immunity in some countries as the interval between the first and second dose becomes …

Background. Influenza A viruses cause occasional pandemics and frequent epidemics.
Licensed influenza vaccines that induce high antibody titers to the highly polymorphic viral …

Background. The novel influenza vaccine MVA-NP+M1 is designed to boost cross-reactive T-cell
responses to internal antigens of the influenza A virus that are conserved across all …

Background Respiratory virus infection is a common cause of hospitalisation in adults. Rapid
point-of-care testing (POCT) for respiratory viruses might improve clinical care by reducing …

Objectives Outpatient parenteral antibiotic therapy (OPAT) is an effective treatment strategy
for a wide variety of infections as long as clinical risk is minimized by conforming to practice …

In this Journal, Zhu et al. recently reported the results of their genomic analysis of multidrug-resistant
Klebsiella pneumoniae isolates from individual patients before and after colistin …